Candel Therapeutics (CADL) Q3 Net Loss Widens To $21.9M; Cash Runway Into Q2 2028
Candel Therapeutics reported a Q3 2026 net loss of $21.9M versus $11.3M in Q3 2025. Cash and cash equivalents were $203.1M at September 30, 2026, and the company expects them to fund operations into Q2 2028.Material DetailsContext by AI AnalystThe results show a clinical-stage company funding incre…